A community-pharmacy survey found substantial long-duration use and reported dose increases. Its design separates users’ descriptions from objectively demonstrated adverse drug reactions.
Ramadan and colleagues collected information through 27 community pharmacies between 2012 and 2014. Alprazolam and bromazepam were the most commonly reported drugs. Anxiety was the leading indication, followed by insomnia and depression.
About 40% reported use for more than a year. Among people using medication for at least a month, 35.5% reported increasing the dose over time. Approximately one-third described perceived adverse effects, and the paper examined potential interacting co-medications.
Self-reported restlessness, behavior changes, or other symptoms cannot automatically be assigned to the benzodiazepine. The authors acknowledged subjective reporting, comorbid disease, co-medications, and possible reluctance to disclose misuse.
The article also contains a participant-count discrepancy: its narrative refers to 786 users while the principal demographic table totals 768. Report that inconsistency rather than converting the paper into a falsely precise population estimate. Recruitment through participating pharmacies further limits extrapolation.
The survey supports asking about duration, changes in dose, alcohol, and medicines from other prescribers. It does not establish a national impairment rate or demonstrate that dose escalation in a specific patient necessarily resulted from tolerance.
Original analysis of the supplied paper: Prescription patterns of benzodiazepines in the Lebanese adult population a cross sectional study. Paper identifier: PMC5019479.